Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Hellerup, CR, DK. The stock last traded at $256.54, up 0.77% on the session, giving a market capitalisation of $15.93B. On trailing twelve-month figures it carries a trailing P/E of 27.14, a net margin of 58.4%. Its beta of 0.38 implies it has historically moved less than the broad market.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Ascendis Pharma A/S is most often compared with the following Healthcare names: